According to Keqian Biotech's announcement, the triple inactivated vaccine for feline rhinotracheitis, calicivirus disease, and panleukopenia declared by the company was approved by the Ministry of Agriculture and Rural Affairs as three new veterinary drugs, and a “New Veterinary Drug Registration Certificate” was issued. The monitoring period was 3 years to prevent the above three feline diseases. The immunization period was 12 months. Approval of this product will enrich the company's product range and enhance market competitiveness. In the future, it is still necessary to obtain a product approval number before it can be marketed. There is uncertainty about the timing and benefits involved.

According to Keqian Biotech's announcement, the triple inactivated vaccine for feline rhinotracheitis, calicivirus disease, and panleukopenia declared by the company was approved by the Ministry of Agriculture and Rural Affairs as three new veterinary drugs, and a “New Veterinary Drug Registration Certificate” was issued. The monitoring period was 3 years to prevent the above three feline diseases. The immunization period was 12 months. Approval of this product will enrich the company's product range and enhance market competitiveness. In the future, it is still necessary to obtain a product approval number before it can be marketed. There is uncertainty about the timing and benefits involved.